Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.
about
Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Safety, pharmacokinetic, and p ...... ed or refractory solid tumors.
@en
Safety, pharmacokinetic, and p ...... ed or refractory solid tumors.
@nl
type
label
Safety, pharmacokinetic, and p ...... ed or refractory solid tumors.
@en
Safety, pharmacokinetic, and p ...... ed or refractory solid tumors.
@nl
prefLabel
Safety, pharmacokinetic, and p ...... ed or refractory solid tumors.
@en
Safety, pharmacokinetic, and p ...... ed or refractory solid tumors.
@nl
P2093
P2860
P1476
Safety, pharmacokinetic, and p ...... ed or refractory solid tumors.
@en
P2093
Hidehisa Noguchi
Masayuki Aoki
Ryota Iwasawa
Shunji Takahashi
Tomohiro Nishina
P2860
P2888
P356
10.1007/S10637-017-0514-4
P577
2017-09-30T00:00:00Z
P6179
1091989412